Self.co, a Vilnius-based digital well being firm serving to customers perceive and handle allergy symptoms and meals intolerances, has raised €2.56 million in a mixed grant and enterprise funding spherical to assist the growth into new markets and additional improvement of Self.co’s proprietary testing expertise and long-term administration instruments.
The funding spherical of €1.2 million was led by Iron Wolf Capital, with participation from Coinvest, NGL Ventures, and a number of other angel buyers. Self.co acquired the €1.36 million grant from Innovation Company Lithuania to enhance its testing expertise.
Tautvydas Gylys, co-founder and CEO of Self.co, stated: “Tens of millions of individuals stay with allergy-like signs however with no actual understanding of what’s inflicting them or what to do about it. We’ve taken superior diagnostic expertise and constructed a easy take a look at system that provides anybody clear, medically legitimate solutions with out the excessive value or lengthy wait.
This elevate for Self.co matches right into a broader European pattern of continued funding in diagnostics and digital well being throughout 2025.
EU-Startups protection exhibits a gradual stream of comparable rounds – as an illustration, CGC Genomics (Switzerland) secured €1.7 million to scale its regulated GenAI platform for genomic evaluation, whereas Cytely (Sweden) raised €3 million to increase its smart-microscopy diagnostic instruments. In Germany, roclub obtained €10 million to advance AI-powered distant operations in medical expertise.
Collectively, these offers underline a transparent 2025 sample of buyers supporting digital and AI-enabled diagnostic platforms that scale back testing prices or improve analytical velocity.
Self.co’s mannequin – integrating molecular allergy testing with digital symptom administration – displays this shift in direction of accessible, data-driven care options.
Whereas most funding exercise stays concentrated in international locations corresponding to Switzerland, Germany, and Sweden, Self.co provides Baltic illustration to this increasing European HealthTech panorama.
“Now the funding will assist us deliver our product to new markets just like the UK, Eire, Austria, and Germany, and deepen ongoing collaboration with healthcare techniques in Poland and Lithuania,” added Gylys.
Based in 2015 by Gintautas Gylys, Self.co is a digital well being and diagnostics firm serving to individuals perceive allergy-like signs by way of molecular testing and knowledgeable steerage.
The corporate controls its whole testing course of, from expertise improvement to lab evaluation. Its proprietary microarray exams analyse 98 allergens and 220 meals sensitivities from a easy blood pattern taken at dwelling or in accomplice clinics.
Past testing, Self.co gives customers with personalised avoidance plans and, when wanted, dietary supplements or therapies, empowering 1000’s to correctly diagnose allergy-like signs and stay more healthy lives.
Kasparas Jurgelionis, Managing Associate at Iron Wolf Capital, says: “As DeepTech buyers, we again applied sciences with the potential to remodel established industries – and that’s precisely what Self.co is doing in allergy diagnostics and care. It is a giant, fast-growing market nonetheless underserved by present options.”
Allergy symptoms and intolerances have an effect on between 30 and 40 % of the worldwide inhabitants, a quantity anticipated to climb to just about 4 billion individuals by mid-century (European Academy of Allergy and Scientific Immunology). Regardless of this prevalence, the corporate argues that prognosis stays one in every of healthcare’s greatest blind spots.
Round 45% of people with allergy-like signs within the EU are both misdiagnosed or by no means identified in any respect (EAACI). Many of those individuals confuse allergy symptoms with different immune or digestive circumstances corresponding to intolerances or sensitivities, resulting in years of uncertainty and ineffective remedy.
The issue is compounded by lengthy ready occasions, typically greater than six months for specialist testing in public techniques, and prohibitive prices. Layers of intermediaries, low take a look at throughput, and supplier prices reportedly create markups on a single molecular allergy take a look at of between €200 and €400. This places correct diagnoses prohibitively out of attain for tens of millions.
In consequence, individuals proceed to stay with fatigue, pores and skin rashes, or digestive signs with out actual solutions, whereas healthcare techniques take in billions in avoidable prices every year.
Self.co’s digital service appears to be like to deal with this with a holistic and scientific strategy. Its core merchandise are two proprietary microarray exams that analyse 98 allergens and 220 meals sensitivities utilizing a easy blood pattern that folks can take at dwelling or in a accomplice clinic.
As soon as evaluated by skilled lab technicians, Self.co gives customers with an in depth avoidance plan and connects them with dietary supplements and coverings as wanted by way of partnerships with native healthcare suppliers.
By controlling your complete testing course of, from expertise improvement to lab evaluation, and eliminating intermediaries, Self.co provides the identical laboratory-grade testing for €69–€99, a fraction of the standard €200–€400 value.
“Tautvydas and the crew mix distinctive business perception with robust execution, giving them a uncommon founder-market match. Self.co’s platform addresses long-standing ache factors for sufferers and clinicians, positioning the corporate to redefine allergy care globally. We’re proud to steer this spherical and assist their mission to ship significant healthcare innovation at scale,” provides Jurgelionis.
Self.co’s testing expertise, developed by allergists and lab specialists, claims to attain molecular-level precision by way of microarray innovation. Superior calibration strategies tailor measurements for every allergen, reportedly guaranteeing accuracy even at very low ranges, whereas delicate fluorescence detection identifies the smallest immune responses. AI then merges medical information and knowledgeable evaluation to ship a personalised, actionable report.
Self.co will use the brand new funding to develop a complete digital well being platform that serves as an entry level for individuals experiencing allergy-like signs. The platform will embrace superior symptom questionnaires to pinpoint circumstances, expanded take a look at choices, and higher integration with conventional healthcare techniques.
Self.co says they’re aiming to grow to be the go-to digital well being platform for top-to-bottom allergy care in Europe by 2030.
